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ABSTRACT 
Porcine circovirus type 2 (PCV2) is a globally distributed virus causing considerable economic losses. It affects mainly piglets 
after the weaning, leading to the disease known as postweaning multisystemic wasting syndrome, whose consequences are 
death or a significant reduction of pigs fattening rate. PCV2 also affects pregnant sows, leading to abortions. There are four 
commercial vaccines against PCV2, two killed vaccines and two recombinant vaccines. All of them are based on PCV2 strains 
of genotype a, which was predominant in the field when the vaccines were marketed. Since live replicative virus could not be 
used as vaccines, these vaccines lead to prevention of symptoms but not to complete viral clearance. Vaccinated and infected 
pigs can still infect other pigs. Today the predominant genotypes are PCV2 b and d. Although the marketed vaccines showed 
cross-protection against heterologous genotypes, it is suboptimal and there are increasing cases of vaccine escape by new 
PCV2 strains. ADL Bionatur Solutions designed and produced three new generation recombinant vaccine candidates, 
BNT029, 030, and 031 with two goals: improve antigenic presentation to achieve better viral clearance and to raise specific 
immunity against the new genotypes. In this project, the vaccine candidates have been tested in vivo for safety and 
immunogenicity in comparison with the current commercial leader, Ingelvac CircoFLEX® from Boehringer Ingelheim. In mice, 
the new candidates raised cell-mediated immunity of higher intensity than that raised by the commercial gold standard, and 
with a more significant Th1-specific component biased to the PCV2b and PCV2d genotypes. In an experimental trial in piglets, 
immunization with BNT029, 030, and 031 did not lead to any adverse effect. The three new candidates led to seroconversion, 
with antibody titers significantly higher than those raised by the commercial gold standard. While the antisera raised  in piglets 
by Ingelvac CircoFLEX predominantly recognized viral antigens derived from a PCV2a strain, the antisera raised by BNT029, 
030, and 031 predominantly recognized viral antigens derived from PCV2b and PCV2d strains. Therefore, we have confirmed 
the initial hypotheses aimed for the new candidates. Currently, we are carrying out serum neutralization assays to confirm that 
the immune response raised by the new candidates in piglets can neutralize effectively the infection by the currently 
predominant viral strains of PCV2. 
REFERENCES 
Beach, N., & Meng, X. (2012). Efficacy and future prospects of commercially available and experimental vaccines against porcine circovirus type 2 (PCV2). 
Virus Research, 164(1-2), 33-42. doi: 10.1016/j.virusres.2011.09.041 
 
Franzo, G., Cortey, M., Segalés, J., Hughes, J., & Drigo, M. (2016). Phylodynamic analysis of porcine circovirus type 2 reveals global waves of emerging 
genotypes and the circulation of recombinant forms. Molecular Phylogenetics And Evolution, 100, 269-280. doi: 10.1016/j.ympev.2016.04.028 
 
Rose, N., Opriessnig, T., Grasland, B., & Jestin, A. (2012). Epidemiology and transmission of porcine circovirus type 2 (PCV2). Virus Research, 164(1-2), 
78-89. doi: 10.1016/j.virusres.2011.12.002  
 
Valli, V., Kiupel, M., Bienzle, D., & Wood, R. (2016). Hematopoietic System. Jubb, Kennedy & Palmer's Pathology Of Domestic Animals: Volume 3, 102-
268.e1. doi: 10.1016/b978-0-7020-5319-1.0001      
 
 
